Background There is no established standard chemotherapy for patients with locally advanced
or metastatic biliary tract cancer. We initially conducted a randomized, phase 2 study …

Background The ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care
based on similar survival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in patients …

Background Immune checkpoint blockade therapy has shown promising results in patients
with advanced hepatocellular carcinoma. We aimed to assess the efficacy and safety of …

Purpose Most patients with hepatocellular carcinoma (HCC) have associated chronic liver
disease, the severity of which is currently assessed by the Child-Pugh (CP) grade. In this …

Context Adjuvant fluorouracil has been shown to be of benefit for patients with resected
pancreatic cancer. Gemcitabine is known to be the most effective agent in advanced disease as …

Background Nanoliposomal irinotecan showed activity in a phase 2 study in patients with
metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based …

Background Advanced biliary tract cancer has a poor prognosis. Cisplatin and gemcitabine
is the standard first-line chemotherapy regimen, but no robust evidence is available for …

Background Despite improvements in multidisciplinary management, patients with biliary
tract cancer have a poor outcome. Only 20% of patients are eligible for surgical resection with …

The overall 5-year survival for pancreatic cancer has changed little over the past few
decades, and pancreatic cancer is predicted to be the second leading cause of cancer-related …

This is a phase II clinical trial investigating the safety and efficacy of intravenous vaccination
with mature autologous dendritic cells (DCs) pulsed ex vivo with a liver tumor cell line lysate …